Alanoud Alshami

I am a skilled clinical and scientific leader with expertise in rare pediatric kidney diseases, transplant immunology, and innovative high-risk transplant procedures. I possess a solid background in generating real-world evidence, clinical epidemiology, and research leadership, with a proven ability to convert intricate clinical insights into impactful scientific and medical strategies. I have experience collaborating with global and national key opinion leaders, shaping scientific strategies, and contributing to policy and ethical governance, including serving on the IPTA Ethics Committee and national kidney allocation committees. I have a successful history of developing and leading multidisciplinary programs, enhancing evidence-based care pathways, and improving medical governance and compliance standards. I am recognized for patient-focused leadership and advocacy, ensuring that the perspectives of children and families are integral to clinical decision-making, policy development, and strategic initiatives. I bring a mission-driven approach that is well-suited for roles in medical affairs, clinical development, and scientific strategy within global biopharmaceutical companies.

• Led the first ABO incompatible pediatric kidney transplant program in the Middle East.
• Performed the first desensitization transplants for highly sensitized patients (cPRA ≥99%) in the Kingdom.
• Pioneered the first surveillance protocol biopsy and DSA monitoring program for low-risk pediatric kidney transplant recipients in the Kingdom, enabling early detection and treatment of subclinical injury and improving long-term graft outcomes; results presented at IPTA Berlin, 2025.
• Published the first pediatric kidney alone transplant in PH1 on Lumasiran in the kingdom and the 3ed international with exceptional outcomes;
• Member of the International PH1 Kidney Alone Working Group (North America).
• Appointed member of the Saudi National Kidney Allocation Committee, shaping national transplant policy.
• Appointed member of the IPTA Ethics Committee, contributing to global transplant ethics.
• Implemented REDCap as the institutional research platform at King Fahad Specialist Hospital.
• Expanded pediatric kidney transplant activity from 8 to 32 cases annually with excellent outcomes.
• Led and published multiple Q1/Q2 studies and contributed as reviewer for international journals.

• Member – Saudi National Kidney Allocation Committee
• Member – IPTA Ethics Committee
• Member – International PH1 Kidney Alone on Lumasiran Working Group
• Associate Editor Organ donation and Transplantation , the official journal of the Saudi Center of Organ Transplant

• Hidden in CAKUT: Primary Hyperoxaluria Type 1 – Pediatric Transplantation (2025)
• Quality of Life in Pediatric CKD – Transplantation Proceedings (2025)
• Pediatric En Bloc Kidney Transplant (
• Vaccine Response in Pediatric RRT – Pediatric Transplantation (2024)
• Polyomavirus Nephropathy Screening – Pediatric Transplantation (2023)
• HLA Sensitization in COVID19 – Transplantation Proceedings (2022)
• SARS CoV 2 Antibody Persistence – BMC Nephrology (2021)
• Antibody Durability Post COVID – Frontiers in Microbiology (2021)
• Hyperkalemic RTA Post Transplant – Pediatric Transplantation (2021)
• Loss of Taste/Smell in COVID19 – PLOS ONE (2020)
• Prednisone Dosing in Nephrotic Syndrome – Pediatric Nephrology (2018)
• Kidney Biopsy Indications in Pediatrics – Pediatric Nephrology (2017)
• Management of Nephrotic Syndrome: GCC Study (2017)
• Protocol Biopsies Driven by De Novo DSA – IPTA Berlin (Oral, 2025)
• Transplants in Children
• Donor–Recipient Size Mismatch – IPTA Berlin (Poster, 2025)
• IVIG for Polyoma Virus Viremia – WCN (Oral, 2023)
• De Novo DSA Post KT – IPTA Vancouver (Oral, 2019)
• Post Transplant Neutropenia & Graft Survival – Transplant International (Oral, 2017)
• ESOT Abstract – European Society for Organ Transplantation (2017)